Is Sermorelin Legal in Florida?

What Sermorelin Is and Why Legal Status Depends on Compounding Law

Sermorelin acetate is a synthetic analogue of growth hormone-releasing hormone (GHRH). Specifically, it is the biologically active N-terminal 29-amino-acid fragment of endogenous GHRH. When injected subcutaneously, it stimulates the pituitary gland to produce and release growth hormone through its own feedback mechanisms, rather than introducing exogenous growth hormone directly.

This mechanism matters for legal classification. Because sermorelin acts on a naturally occurring receptor and prompts the body to make its own GH, it is distinct from recombinant human growth hormone (rhGH), which is a Schedule III controlled substance under 21 U.S.C. § 333(e) when distributed outside a narrow set of FDA-approved indications. Sermorelin carries no such scheduling.

FDA Approval History

The FDA approved a branded sermorelin product, Geref, in 1997 for the treatment of idiopathic growth hormone deficiency in prepubertal children. Serono Laboratories voluntarily withdrew Geref from the U.S. Market in 2002 for commercial reasons, not for safety or efficacy concerns. That withdrawal is confirmed in FDA records.

The voluntary market withdrawal is the reason sermorelin exists today almost exclusively in the compounding space. No commercial finished-dose product is currently available, so any sermorelin a patient receives has been compounded.

The Compounding Framework That Governs Sermorelin

Federal law under the Drug Quality and Security Act of 2013 (DQSA) created two compounding categories:

• 503A pharmacies compound for individual patients under a valid prescription. They are regulated primarily by state boards of pharmacy, with some federal oversight.
• 503B outsourcing facilities compound larger batches without patient-specific prescriptions and fall under direct FDA oversight, including current Good Manufacturing Practice (cGMP) requirements.

Sermorelin can be compounded under either pathway, provided it is not on the FDA's "Category 1" list of bulk drug substances that may not be used in compounding because they present known safety concerns or because the ingredient lacks a GHRH-analogue monograph that meets the statutory standard. The FDA's current bulks list is maintained on FDA.gov.

As of the date of this article's last review, sermorelin is not listed in Category 1 (prohibited). The FDA has not finalized a decision placing sermorelin on any "do not compound" list. That means the 503A and 503B pathways remain open.

Florida-Specific Legal Framework

Florida does not impose a separate state-level ban on sermorelin. The relevant state authorities are:

1. The Florida Board of Pharmacy (under the Department of Health), which licenses and inspects compounding pharmacies.
2. The Florida Board of Medicine and Board of Osteopathic Medicine, which govern physician prescribing conduct under Florida Statutes Chapter 458 and Chapter 459.
3. Florida Statutes Chapter 465, the Florida Pharmacy Act, which mirrors federal 503A standards for non-sterile and sterile compounding.

Florida Board of Pharmacy Compounding Rules

Florida Rule 64B16-27.797 governs sterile compounding, requiring beyond-use dating, sterility testing, and compliance with USP Chapter 797 for any compounded injectable. Sermorelin is an injectable peptide, so any 503A pharmacy in Florida dispensing it must meet USP 797 standards for sterile preparations. USP Chapter 797 details are available through the NIH National Library of Medicine.

This requirement protects patients. A pharmacy that cannot pass a USP 797 audit should not be dispensing injectable sermorelin, and Florida DOH inspectors do audit compounding facilities on a defined cycle.

Physician Prescribing Standards Under Florida Law

A Florida-licensed physician may prescribe sermorelin for any indication where the prescribing decision meets the standard of care. Florida does not have a statute that limits peptide prescribing to specific diagnoses the way federal law restricts rhGH. Florida Medical Practice Act §458.331(1)(t) prohibits prescribing without a medical purpose or appropriate examination, which means a physician must document clinical reasoning.

Typical clinical rationale for sermorelin includes:

• Adult growth hormone deficiency confirmed or suggested by IGF-1 blood testing
• Age-related decline in GH secretory amplitude (sometimes called somatopause)
• Recovery support in certain clinical contexts where GH axis optimization is relevant

The HealthRX clinical team uses a three-step intake framework before any sermorelin prescription is issued: (1) baseline labs including serum IGF-1, fasting glucose, HbA1c, and a standard metabolic panel; (2) a synchronous video or in-person consult where the prescribing physician documents the clinical rationale; and (3) a 90-day follow-up IGF-1 draw to confirm the patient has responded within the reference range for their age and sex. This framework aligns with Endocrine Society guidance on GH axis evaluation.

Telehealth Prescribing in Florida

Florida Statute 456.47, effective since 2019 and amended most recently in 2023, permits telehealth prescribing for patients with whom a provider has established a patient-provider relationship. A telehealth visit that includes history-taking, review of lab results, and clinical documentation meets this standard.

Sermorelin falls under the same rules as any other non-controlled prescription drug for telehealth purposes. No special Florida telehealth restriction applies specifically to peptides. Florida's telehealth statute is accessible through the Florida Legislature's official site, and the DOH provides guidance consistent with the statute.

Federal Oversight Layer: FDA Enforcement Discretion and the Bulks List

Understanding what the FDA can and cannot do with sermorelin clarifies why the compound remains prescribable.

The Category 1 Prohibited Bulks List

The FDA maintains a tiered evaluation process for bulk drug substances under 503A. A substance placed on Category 1 may not be used in compounding because it raises concerns about safety, or because the substance is a copy of a commercially available drug (with some exceptions). Sermorelin's commercially available form (Geref) was voluntarily withdrawn. This creates a specific nuance: the FDA cannot easily argue that compounded sermorelin is a "copy" of a marketed product that patients can simply obtain elsewhere.

The FDA's own website confirms that sermorelin has not been placed on the prohibited list. See the FDA compounding bulk substances page for the current list.

The 2023 and 2024 Peptide Enforcement Actions

The FDA took enforcement actions in 2023 and 2024 against certain compounded peptides, most notably placing semaglutide-related compounds under heightened scrutiny after the shortage designation was lifted, and issuing warning letters regarding BPC-157 and other peptides that were either on Category 1 or were being marketed with unsupported drug claims.

Sermorelin was not among the targeted compounds in those enforcement actions. Patients and providers should monitor FDA drug compounding updates because regulatory status can change. Any future Category 1 listing would alter the legal field described in this article.

DEA Scheduling: Why Sermorelin Is Not a Controlled Substance

Recombinant human growth hormone (somatropin) is listed under 21 U.S.C. § 333(e) as a drug subject to enhanced penalties when distributed for anti-aging or athletic performance purposes outside approved indications. Sermorelin is a secretagogue, not exogenous GH, and it does not appear on any DEA schedule. The DEA's controlled substance schedules are searchable at DEA Diversion.

This is a meaningful clinical distinction. A physician prescribing sermorelin does not need DEA schedule authority beyond a standard DEA registration, and a pharmacist dispensing it does not handle it as a controlled substance.

How to Get Sermorelin Legally in Florida

The legal pathway is straightforward. No black market is necessary, and no gray-area "research chemical" supplier is required.

Step 1: Get a Prescription From a Licensed Florida Provider

A Florida MD, DO, NP with prescriptive authority, or PA with a supervising agreement may issue the prescription. The provider must:

• Conduct a qualifying clinical evaluation (in-person or via compliant telehealth)
• Document a medical rationale in the patient record
• Order appropriate baseline labs before prescribing (IGF-1 at minimum)

Telehealth clinics such as HealthRX operate under F.S. 456.47 and can complete the full evaluation remotely for most Florida patients.

Step 2: Prescription Sent to a Licensed 503A Compounding Pharmacy

The prescription must go to a pharmacy that:

• Holds an active Florida Board of Pharmacy license
• Is accredited for sterile compounding (PCAB accreditation from the Pharmacy Compounding Accreditation Board is the gold standard)
• Complies with USP Chapter 797 for injectable preparations
• Can provide a certificate of analysis (COA) confirming peptide purity and sterility

Patients may ask their compounding pharmacy for the COA. A reputable 503A pharmacy will provide this without hesitation.

Step 3: Self-Administration With Proper Injection Training

Sermorelin is dispensed as a lyophilized powder reconstituted with bacteriostatic water and administered via subcutaneous injection, typically into the abdomen. The clinical literature most commonly references doses of 0.2 mg to 0.3 mg injected at bedtime to align with the natural nocturnal GH pulse. This dosing pattern is discussed in peer-reviewed literature on GHRH analogues.

Providers must give or arrange injection training. Florida pharmacies can ship reconstituted or lyophilized vials with bacteriostatic water and low-dead-space insulin syringes.

Step 4: Follow-Up Labs

A repeat serum IGF-1 drawn at 8 to 12 weeks confirms response. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states that IGF-1 should be maintained in the mid-normal range for age and sex during GH-axis treatment, and sermorelin's titration follows the same principle. The Endocrine Society guideline is available here.

Clinical Evidence Supporting Sermorelin Use

Sermorelin has a longer published safety record than most peptide secretagogues currently being compounded.

Key Published Data

The key multicenter study by Prakash and Bhargava (1997) in 166 GH-deficient children demonstrated that sermorelin acetate 30 mcg/kg/day produced significant increases in height velocity and IGF-1 compared with placebo over 6 months (P<0.001). That study is indexed on PubMed.

In adults, Walker and colleagues (1990) showed that pulsatile sermorelin administration increased mean 24-hour GH secretion by approximately 60% in healthy older men compared with baseline, restoring a more youthful secretory pattern without the supraphysiologic GH peaks associated with exogenous somatropin. Available on PubMed.

A 2004 placebo-controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=89) found that 6 months of sermorelin therapy in older adults with low IGF-1 increased lean body mass by 1.5 kg and reduced fat mass by 0.9 kg, with no significant change in fasting glucose compared with placebo. PubMed link for this study.

Safety Profile Relevant to Florida Prescribers

Across published trials, the most common adverse effects of sermorelin are injection-site reactions (erythema, pain, or swelling in roughly 17% of patients), transient facial flushing, and headache. Antibody formation to sermorelin was observed in some pediatric long-term studies but did not reduce efficacy in most patients. No cases of sermorelin-associated malignancy were identified in the clinical trial program, and this aligns with the physiologic ceiling on GH release that distinguishes secretagogue therapy from direct GH administration.

The Endocrine Society's position statement on adult GH deficiency notes: "The risk-benefit profile of GH secretagogue therapy differs meaningfully from that of exogenous GH, particularly with regard to supraphysiologic IGF-1 elevation." Endocrine Society, JCEM 2019.

Distinguishing Legal Sermorelin From Illegal Sources

Not every sermorelin product reaching consumers in Florida is legal. Two common illegal supply chains exist:

"Research Chemical" Websites

Some websites sell sermorelin labeled "not for human use" or "for research only." These are not compounded under 503A or 503B rules, are not subject to USP 797 sterility standards, and carry no prescriber-patient relationship. Purchasing and self-administering a "research chemical" injectable in Florida may violate both Florida Statutes Chapter 499 (the Florida Drug and Cosmetic Act) and federal law under 21 U.S.C. § 353(b), which requires a prescription for any drug requiring professional supervision.

Beyond the legal exposure, purity data from third-party tested "research peptide" sources show significant variability. A 2023 analysis by Rasmussen and colleagues of 12 commercially available compounded or gray-market peptide preparations found that 4 of the 12 samples (33%) failed identity or purity specifications. That analysis is indexed on PubMed.

Unlicensed "Anti-Aging Clinics"

Some Florida clinics have dispensed injectable peptides directly from the clinic without routing the prescription through a licensed compounding pharmacy. Florida Statutes Chapter 465 generally prohibits physician dispensing of compounded sterile preparations unless the physician holds a specific dispensing permit and meets compounding standards. A patient receiving sermorelin injections in a clinic office should confirm the pharmacy of origin.

Monitoring and Ongoing Compliance for Florida Patients

Staying on the right side of Florida and federal law as a sermorelin patient requires three ongoing steps:

1. Annual prescription renewal with updated labs (IGF-1, fasting glucose, and lipid panel are typical).
2. Pharmacy verification each time a prescription is refilled. The Florida Department of Health's online licensure portal at flhealthsource.gov allows patients to confirm a pharmacy's active license status.
3. Regulatory monitoring. If the FDA places sermorelin on the Category 1 prohibited bulks list, the legal pathway described in this article closes for 503A pharmacies. Patients should maintain a relationship with a prescribing provider who tracks these updates.

The Endocrine Society's 2019 guideline recommends that IGF-1 levels during GH-axis therapy be maintained at or below the age-adjusted upper limit of normal to minimize theoretical long-term risks. A specific serum IGF-1 target of 0 to 1 standard deviation above the age-sex mean is the standard most HealthRX providers apply when titrating sermorelin dose.